Naropin
- Product NDC
- 63323-288
- Requested package NDC
- 63323-288-27
- 11-digit product format
- 633230288
- Labeler code
- 63323
- Product ID
- 63323-288_73218c89-8925-468c-84bf-9960b4b3dc3c
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- ROPIVACAINE HYDROCHLORIDE
- Dosage form
- INJECTION, SOLUTION
- Route
- EPIDURAL
- Labeler
- Fresenius Kabi USA, LLC
- Application
- NDA020533
- Marketing category
- NDA
- Marketing start
- 2009-08-04
- Substance
- ROPIVACAINE HYDROCHLORIDE
- Active strength
- 10 mg/mL
- Pharmacologic classes
- Amide Local Anesthetic [EPC], Amides [CS], Local Anesthesia [PE]
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N020533-001 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 20MG/10ML (2MG/ML) | SOLUTION / INJECTION | AP | RLD | 1998-05-01 |
| N020533-002 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 40MG/20ML (2MG/ML) | SOLUTION / INJECTION | AP | RLD | 1996-09-24 |
| N020533-003 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 100MG/20ML (5MG/ML) | SOLUTION / INJECTION | AP | RLD | 1998-05-01 |
| N020533-004 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 150MG/20ML (7.5MG/ML) | SOLUTION / INJECTION | AP | RLD | 1996-09-24 |
| N020533-005 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 100MG/10ML (10MG/ML) | SOLUTION / INJECTION | AP | RLD | 1996-09-24 |
| N020533-006 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 200MG/100ML (2MG/ML) | SOLUTION / INJECTION | AP | RLD | 1996-09-24 |
| N020533-007 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 400MG/200ML (2MG/ML) | SOLUTION / INJECTION | AP | RLD | 1996-09-24 |
| N020533-008 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 150MG/30ML (5MG/ML) | SOLUTION / INJECTION | AP | RLD | 1996-09-24 |
| N020533-009 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 500MG/100ML (5MG/ML) | SOLUTION / INJECTION | AP | RLD | 2011-01-04 |
| N020533-010 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 1GM/200ML (5MG/ML) | SOLUTION / INJECTION | AP | RLD | 2011-01-04 |
| N020533-011 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 200MG/20ML (10MG/ML) | SOLUTION / INJECTION | AP | RLD, RS | 1996-09-24 |
| N020533-012 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 75MG/10ML (7.5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / INJECTION | RLD | 1996-09-24 | |
| N020533-013 | NAROPIN | ROPIVACAINE HYDROCHLORIDE | 50MG/10ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / INJECTION | RLD | 1998-05-01 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| N020533-001 | AP |
| N020533-002 | AP |
| N020533-003 | AP |
| N020533-004 | AP |
| N020533-005 | AP |
| N020533-006 | AP |
| N020533-007 | AP |
| N020533-008 | AP |
| N020533-009 | AP |
| N020533-010 | AP |
| N020533-011 | AP |
Orange Book patents#
| Application-product | Patent | Expiration | Use code | Coverage / status | Submission date |
|---|---|---|---|---|---|
| N020533-006 | 7857802 | 2026-11-28 | Drug product | 2014-11-06 | |
| N020533-007 | 7857802 | 2026-11-28 | Drug product | 2014-11-06 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N020533-001 | NAROPIN | 20MG/10ML (2MG/ML) | SOLUTION / INJECTION | AP | RLD | 1998-05-01 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-002 | NAROPIN | 40MG/20ML (2MG/ML) | SOLUTION / INJECTION | AP | RLD | 1996-09-24 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-003 | NAROPIN | 100MG/20ML (5MG/ML) | SOLUTION / INJECTION | AP | RLD | 1998-05-01 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-004 | NAROPIN | 150MG/20ML (7.5MG/ML) | SOLUTION / INJECTION | AP | RLD | 1996-09-24 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-005 | NAROPIN | 100MG/10ML (10MG/ML) | SOLUTION / INJECTION | AP | RLD | 1996-09-24 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-006 | NAROPIN | 200MG/100ML (2MG/ML) | SOLUTION / INJECTION | AP | RLD | 1996-09-24 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-007 | NAROPIN | 400MG/200ML (2MG/ML) | SOLUTION / INJECTION | AP | RLD | 1996-09-24 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-008 | NAROPIN | 150MG/30ML (5MG/ML) | SOLUTION / INJECTION | AP | RLD | 1996-09-24 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-009 | NAROPIN | 500MG/100ML (5MG/ML) | SOLUTION / INJECTION | AP | RLD | 2011-01-04 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-010 | NAROPIN | 1GM/200ML (5MG/ML) | SOLUTION / INJECTION | AP | RLD | 2011-01-04 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-011 | NAROPIN | 200MG/20ML (10MG/ML) | SOLUTION / INJECTION | AP | RLD, RS | 1996-09-24 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-012 | NAROPIN | 75MG/10ML (7.5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / INJECTION | RLD | 1996-09-24 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N020533-013 | NAROPIN | 50MG/10ML (5MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION / INJECTION | RLD | 1998-05-01 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N020533-001 | AP | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-002 | AP | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-003 | AP | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-004 | AP | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-005 | AP | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-006 | AP | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-007 | AP | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-008 | AP | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-009 | AP | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-010 | AP | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | N020533-011 | AP | 1 | a50c72e98297… |
Observed Orange Book patent history#
| Captured | Edition | Application-product | Patent | Expiration | Use code | Coverage / status | Submission date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | N020533-006 | 7857802 | 2026-11-28 | Drug product | 2014-11-06 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | N020533-007 | 7857802 | 2026-11-28 | Drug product | 2014-11-06 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| NAROPIN | ROPIVACAINE HYDROCHLORIDE | Henry Schein, Inc. | 6a2f1f6d-026f-4f39-aee0-5b75b8eb5c02 | 2026-07-22 | Warnings, Adverse reactions | 020533 NDA020533 |
| Naropin | ROPIVACAINE HYDROCHLORIDE | Fresenius Kabi USA, LLC | cb6583ff-cde4-4280-aa5b-0bea2b844792 | 2026-07-17 | Warnings, Adverse reactions | 020533 NDA020533 |
| Naropin | ROPIVACAINE HYDROCHLORIDE | Fresenius Kabi USA, LLC | dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7 | 2024-08-15 | Warnings, Adverse reactions | 020533 NDA020533 |
| Naropin | ROPIVACAINE HYDROCHLORIDE | Fresenius Kabi USA, LLC | 23d2d448-a744-4877-9f2d-7e57c198da89 | 2024-08-06 | Warnings, Adverse reactions | 020533 NDA020533 63323-288 |
| Naropin | ROPIVACAINE HYDROCHLORIDE | Fresenius Kabi USA, LLC | c6613708-c1f7-4f5c-91a3-ebbc1d7905c6 | 2024-07-10 | Warnings, Adverse reactions | 020533 NDA020533 63323-288 |
| Naropin | ROPIVACAINE HYDROCHLORIDE | Fresenius Kabi USA, LLC | 56dfabf7-f7a8-4601-b17a-cb16fb995b0f | 2024-05-22 | Warnings, Adverse reactions | 020533 NDA020533 63323-288-27 63323-288 63323028827 |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Naropin
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| ROPIVACAINE HYDROCHLORIDE | 10 mg/mL |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| V910P86109 | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 1734084 | Internal RxNorm lookup |
| 1734086 | Internal RxNorm lookup |
| 1734090 | Internal RxNorm lookup |
| 1734091 | Internal RxNorm lookup |
| 1734203 | Internal RxNorm lookup |
| 1734204 | Internal RxNorm lookup |
| 1734207 | Internal RxNorm lookup |
| 1734208 | Internal RxNorm lookup |
| 1734347 | Internal RxNorm lookup |
| 1734348 | Internal RxNorm lookup |
| 1734355 | Internal RxNorm lookup |
| 1734356 | Internal RxNorm lookup |
| 1734475 | Internal RxNorm lookup |
| 1734476 | Internal RxNorm lookup |
| 1734479 | Internal RxNorm lookup |
| 1734480 | Internal RxNorm lookup |
| 1734481 | Internal RxNorm lookup |
| 1734482 | Internal RxNorm lookup |
| 1734483 | Internal RxNorm lookup |
| 1734484 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| c6613708-c1f7-4f5c-91a3-ebbc1d7905c6 | Available on FDA.report |
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 387afa15-cb51-403a-b2e2-1c9d201e07dc | Product name | 9 | 20230426 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-288-01 | Naropin | 10 mL in 1 AMPULE | INJECTION, SOLUTION | 10 | 27 | |
| 63323-288-03 | Naropin | 10 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 10 | 27 | |
| 63323-288-06 | Naropin | 20 mL in 1 AMPULE | INJECTION, SOLUTION | 20 | 27 | |
| 63323-288-07 | Naropin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 20 | 27 | |
| 63323-288-10 | Naropin | 5 in 1 BOX | INJECTION, SOLUTION | 5 | 27 | |
| 63323-288-11 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 27 | |
| 63323-288-20 | Naropin | 5 in 1 BOX | INJECTION, SOLUTION | 5 | 27 | |
| 63323-288-21 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 27 | |
| 63323-288-23 | Naropin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 20 | 8 | |
| 63323-288-29 | Naropin | 25 in 1 TRAY | INJECTION, SOLUTION | 25 | 8 | |
| 63323-288-25 | Naropin | 20 mL in 1 AMPULE | INJECTION, SOLUTION | 20 | 5 | |
| 63323-288-27 | Naropin | 5 in 1 BOX | INJECTION, SOLUTION | 5 | 5 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 63323-288-01 | ML - Milliliter | 63323-288 | 99d30a29-0827-4f56-871e-74fff2b21d2a | 1 | 2025-09-12 |
| 63323-288-06 | ML - Milliliter | 63323-288 | 0b27ce34-0c40-470b-baa5-cd6d736138a9 | 1 | 2021-06-02 |
| 63323-288-07 | ML - Milliliter | 63323-288 | e450eecd-0e8b-4c29-8b4e-70132736db56 | 1 | 2024-08-12 |
| 63323-288-10 | ML - Milliliter | 63323-288 | 3332880c-79cc-46fc-b3fe-0d5e98caedb9 | 1 | 2012-07-24 |
| 63323-288-11 | ML - Milliliter | 63323-288 | cfbf6146-ab02-4290-b393-9e6cf57f0bdb | 1 | 2013-02-13 |
| 63323-288-20 | ML - Milliliter | 63323-288 | d1bf23e5-a796-4fd1-be7d-d04e794afc02 | 1 | 2012-07-24 |
| 63323-288-21 | ML - Milliliter | 63323-288 | 28b72b1c-78b4-463a-baf5-f1249b7071d8 | 1 | 2013-02-13 |
| 63323-288-23 | ML - Milliliter | 63323-288 | 57c7d0ae-4b9d-4fa9-a9b4-015794be2d20 | 1 | 2024-07-12 |
| 63323-288-27 | ML - Milliliter | 63323-288 | 67d56f56-df1f-4127-896a-1e29cb3fd63f | 1 | 2014-04-03 |
| 63323-288-29 | ML - Milliliter | 63323-288 | f2b1e7d0-d777-41f2-a2a2-b4a33d62a096 | 1 | 2014-04-03 |
DailyMed Socrata Ingredients#
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63323-288 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 27 | Current NDC, Legacy NDC, 8 package rows | 20240814_23d2d448-a744-4877-9f2d-7e57c198da89.zip |
| 63323-288 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 8 | Current NDC, Legacy NDC, 2 package rows | 20240817_c6613708-c1f7-4f5c-91a3-ebbc1d7905c6.zip |
| 63323-288 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC] | 5 | Current NDC, Legacy NDC, 2 package rows | 20240524_56dfabf7-f7a8-4601-b17a-cb16fb995b0f.zip |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 1734204 | Naropin 0.2 % in 10 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734348 | Naropin 0.2 % in 100 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734208 | Naropin 0.2 % in 20 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734356 | Naropin 0.2 % in 200 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734480 | Naropin 0.5 % in 100 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734484 | Naropin 0.5 % in 20 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734482 | Naropin 0.5 % in 200 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734476 | Naropin 0.5 % in 30 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 905191 | Naropin 0.75 % in 20 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734091 | Naropin 1 % in 10 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734086 | Naropin 1 % in 20 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734203 | ROPivacaine HCl 0.2 % in 10 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734347 | ROPivacaine HCl 0.2 % in 100 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734207 | ROPivacaine HCl 0.2 % in 20 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734355 | ROPivacaine HCl 0.2 % in 200 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734479 | ROPivacaine HCl 0.5 % in 100 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734483 | ROPivacaine HCl 0.5 % in 20 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734481 | ROPivacaine HCl 0.5 % in 200 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734475 | ROPivacaine HCl 0.5 % in 30 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 905189 | ROPivacaine HCl 0.75 % in 20 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734090 | ROPivacaine HCl 1 % in 10 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734084 | ROPivacaine HCl 1 % in 20 ML Injection | PSN | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734091 | 10 ML ropivacaine hydrochloride 10 MG/ML Injection [Naropin] | SBD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734204 | 10 ML ropivacaine hydrochloride 2 MG/ML Injection [Naropin] | SBD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734348 | 100 ML ropivacaine hydrochloride 2 MG/ML Injection [Naropin] | SBD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734480 | 100 ML ropivacaine hydrochloride 5 MG/ML Injection [Naropin] | SBD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734086 | 20 ML ropivacaine hydrochloride 10 MG/ML Injection [Naropin] | SBD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734208 | 20 ML ropivacaine hydrochloride 2 MG/ML Injection [Naropin] | SBD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734484 | 20 ML ropivacaine hydrochloride 5 MG/ML Injection [Naropin] | SBD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 905191 | 20 ML ropivacaine hydrochloride 7.5 MG/ML Injection [Naropin] | SBD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734356 | 200 ML ropivacaine hydrochloride 2 MG/ML Injection [Naropin] | SBD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734482 | 200 ML ropivacaine hydrochloride 5 MG/ML Injection [Naropin] | SBD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734476 | 30 ML ropivacaine hydrochloride 5 MG/ML Injection [Naropin] | SBD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734090 | 10 ML ropivacaine hydrochloride 10 MG/ML Injection | SCD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734203 | 10 ML ropivacaine hydrochloride 2 MG/ML Injection | SCD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734347 | 100 ML ropivacaine hydrochloride 2 MG/ML Injection | SCD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734479 | 100 ML ropivacaine hydrochloride 5 MG/ML Injection | SCD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734084 | 20 ML ropivacaine hydrochloride 10 MG/ML Injection | SCD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734207 | 20 ML ropivacaine hydrochloride 2 MG/ML Injection | SCD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734483 | 20 ML ropivacaine hydrochloride 5 MG/ML Injection | SCD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 905189 | 20 ML ropivacaine hydrochloride 7.5 MG/ML Injection | SCD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734355 | 200 ML ropivacaine hydrochloride 2 MG/ML Injection | SCD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734481 | 200 ML ropivacaine hydrochloride 5 MG/ML Injection | SCD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734475 | 30 ML ropivacaine hydrochloride 5 MG/ML Injection | SCD | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734091 | 10 ML Naropin 10 MG/ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734204 | 10 ML Naropin 2 MG/ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734348 | 100 ML Naropin 2 MG/ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734480 | 100 ML Naropin 5 MG/ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734086 | 20 ML Naropin 10 MG/ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734208 | 20 ML Naropin 2 MG/ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734484 | 20 ML Naropin 5 MG/ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 905191 | 20 ML Naropin 7.5 MG/ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734356 | 200 ML Naropin 2 MG/ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734482 | 200 ML Naropin 5 MG/ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734476 | 30 ML Naropin 5 MG/ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734204 | Naropin 0.2 % per 10 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734348 | Naropin 0.2 % per 100 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734208 | Naropin 0.2 % per 20 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734356 | Naropin 0.2 % per 200 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734480 | Naropin 0.5 % per 100 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734484 | Naropin 0.5 % per 20 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734482 | Naropin 0.5 % per 200 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734476 | Naropin 0.5 % per 30 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 905191 | Naropin 0.75 % per 20 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734091 | Naropin 1 % per 10 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734086 | Naropin 1 % per 20 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734091 | Naropin 100 MG per 10 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734484 | Naropin 100 MG per 20 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734482 | Naropin 1000 MG per 200 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 905191 | Naropin 150 MG per 20 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734476 | Naropin 150 MG per 30 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734204 | Naropin 20 MG per 10 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734348 | Naropin 200 MG per 100 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734086 | Naropin 200 MG per 20 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734208 | Naropin 40 MG per 20 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734356 | Naropin 400 MG per 200 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734480 | Naropin 500 MG per 100 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734203 | ropivacaine HCl 0.2 % per 10 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734347 | ropivacaine HCl 0.2 % per 100 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
| 1734207 | ropivacaine HCl 0.2 % per 20 ML Injection | SY | 23d2d448-a744-4877-9f2d-7e57c198da89 | 27 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 63323-288-27 | 63323028827 | 5 AMPULE in 1 BOX (63323-288-27) / 20 mL in 1 AMPULE (63323-288-25) | 5 ampule | 2009-08-04 | 0000-00-00 | No | No | Current |